A detailed history of First Horizon Advisors, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 1,090 shares of SUPN stock, worth $41,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,090
Previous 1,090 -0.0%
Holding current value
$41,757
Previous $29,000 13.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$25.99 - $33.85 $2,936 - $3,825
-113 Reduced 9.39%
1,090 $29,000
Q4 2023

Feb 06, 2024

SELL
$22.72 - $29.68 $4,793 - $6,262
-211 Reduced 14.92%
1,203 $34,000
Q2 2023

Aug 03, 2023

BUY
$29.91 - $38.73 $6,311 - $8,172
211 Added 17.54%
1,414 $42,000
Q2 2022

Aug 02, 2022

BUY
$25.33 - $34.25 $30,471 - $41,202
1,203 New
1,203 $34,000
Q1 2022

May 10, 2022

SELL
$28.51 - $32.9 $42,365 - $48,889
-1,486 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$26.37 - $34.22 $7,462 - $9,684
283 Added 23.52%
1,486 $43,000
Q3 2021

Nov 15, 2021

BUY
$23.54 - $31.39 $25,776 - $34,372
1,095 Added 1013.89%
1,203 $32,000
Q3 2021

Nov 09, 2021

SELL
$23.54 - $31.39 $25,776 - $34,372
-1,095 Reduced 91.02%
108 $2,000
Q2 2021

Aug 09, 2021

SELL
$26.72 - $33.19 $3,473 - $4,314
-130 Reduced 9.75%
1,203 $37,000
Q1 2021

May 11, 2021

BUY
$24.15 - $31.45 $16,542 - $21,543
685 Added 105.71%
1,333 $34,000
Q4 2020

Feb 11, 2021

BUY
$17.7 - $25.81 $3,964 - $5,781
224 Added 52.83%
648 $16,000
Q2 2020

Jul 31, 2020

BUY
$17.09 - $24.89 $7,246 - $10,553
424 New
424 $10,000
Q3 2019

Oct 23, 2019

SELL
$25.47 - $33.37 $14,110 - $18,486
-554 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
554
554 $0

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.05B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.